(NASDAQ: RNXT) Renovorx's forecast annual revenue growth rate of 222.3% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.71%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Renovorx's revenue in 2025 is $662,000.On average, 2 Wall Street analysts forecast RNXT's revenue for 2025 to be $55,152,055, with the lowest RNXT revenue forecast at $45,807,355, and the highest RNXT revenue forecast at $64,496,756. On average, 2 Wall Street analysts forecast RNXT's revenue for 2026 to be $176,816,390, with the lowest RNXT revenue forecast at $164,906,478, and the highest RNXT revenue forecast at $188,726,303.
In 2027, RNXT is forecast to generate $1,017,656,199 in revenue, with the lowest revenue forecast at $1,017,656,199 and the highest revenue forecast at $1,017,656,199.